Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs. Zanubru…
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Narrative review links myasthenia gravis and autoimmune encephalitis risk
MG and Brain Inflammation Linked in New Review
This narrative review examines the association between myasthenia gravis and autoimmune encephalitis. It synthesizes epidemiological data an…
This review reveals that myasthenia gravis is often linked to brain inflammation — and that may change how doctors treat tough cases.
Sequential efgartigimod and rituximab induced improvement in three patients with refractory autoimmune encephalitis
Sequential efgartigimod and rituximab showed improvement in three patients with autoimmune encephalitis
This case series describes three patients with refractory autoimmune encephalitis treated with sequential efgartigimod and rituximab. All th…
Three patients with difficult autoimmune encephalitis improved after sequential treatment, suggesting a potential new option for those who d…
Rituximab use in interstitial pneumonia with autoimmune features shows similar outcomes to control group
Rituximab shows similar outcomes for IPAF patients in small study
This retrospective case-control study of 14 rituximab-treated and 19 control patients with interstitial pneumonia with autoimmune features f…
A small study found that patients with a rare lung condition had similar outcomes whether they received rituximab or not, suggesting limited…
Rituximab Shows Long-Term Remission in Pediatric Steroid-Dependent Nephrotic Syndrome
Rituximab Helps Kids With Kidney Swelling
This retrospective cohort study of 42 children with steroid-dependent or frequently relapsing nephrotic syndrome found that rituximab led to…
Imagine a child who needs medicine just to stay dry.
Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients
New Dosing Strategy Helps Kidney Disease Patients Who Didn’t Respond to Standard Treatment
This single-center retrospective cohort study evaluated 33 patients with refractory membranous nephropathy treated with a B-cell reconstitut…
For patients with a stubborn kidney disease who ran out of options, a smarter dosing strategy may offer a new path to recovery.
Retrospective review of tocilizumab, rituximab, and azathioprine in chronic relapsing inflammatory optic neuropathy
New Clue Found in Stubborn Eye Inflammation
This retrospective analysis reviews tocilizumab, rituximab, and azathioprine use in 60 patients with chronic relapsing inflammatory optic ne…
Knowing a patient's blood marker status can guide doctors to the right therapy to stop recurring eye inflammation.
Systematic review of immunosuppression for SLE-associated intestinal pseudo-obstruction
SLE Can Shut Down the Gut — But It Might Be Reversible
This review synthesized 43 cases of SLE-associated intestinal pseudo-obstruction. Corticosteroids were used in all patients, with variable u…
Lupus can paralyze the gut without a blockage, but early treatment with immunosuppressives often reverses this dangerous complication.
Scoping review synthesizes immunosuppressive strategies and outcomes in solid organ transplantation
New Drug Strategies Aim to Stop Your Body From Rejecting a Transplant
This scoping review examines immunosuppressive strategies for solid organ transplant patients, including conventional, biologic, and emergin…
New drug strategies aim to stop your body from attacking a new organ, protecting transplants longer while reducing dangerous side effects fr…
Switching therapy after rituximab resistance in AQP4-IgG+ NMOSD shows variable relapse outcomes.
New Hope for Tough-to-Treat Nerve Disorder
This single-center, retrospective case series of 10 adults with AQP4-IgG+ NMOSD who were resistant to rituximab evaluated switching therapy.…
Patients with a rare nerve disease who stopped responding to standard treatment found relief after switching to new therapies that prevented…
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients.
Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases. Pharmacokinetics were found to be highly h…
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
Phase 1b trial of intravenous B001 shows favorable safety in aquaporin-4-positive NMOSD patients.
A New MS-Like Disease Drug Passes Its First Human Safety Test
This Phase 1b randomized, double-blind, placebo-controlled trial evaluated intravenous B001 in 22 patients with aquaporin-4 immunoglobulin G…
A new drug for a rare nerve disease that can cause blindness and paralysis passed its first human safety test with no severe side effects se…